5 terminated. 5 Phase 2, 1 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 5 | Terminated 5 |
| Phase 1 | 1 | Terminated 1 |
Follow Craniosynostoses: new trials by email Literature Review of Craniosynostoses trials Research Report on Craniosynostoses
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Derazantinib Alone or in Combination With Paclitaxel, Ramucirumab or Atezolizumab in Gastric Adenocarcinoma Derazantinib, Derazantinib-paclitaxel-ramucirumab combination - Gastric Adenocarcinoma | Phase 1 / Phase 2 | Terminated | Basilea Pharmaceutica | 47 | 2020-10-06 | 2024-04-04 |
| Pemigatinib + Pembrolizumab vs Pemigatinib Alone vs Standard of Care for Urothelial Carcinoma (FIGHT-205) Pemigatinib, Pembrolizumab, Gemcitabine - Metastatic Urothelial Carcinoma, Unresectable Urothelial Carcinoma | Phase 2 | Terminated | Incyte Corporation | 7 | 2020-05-14 | 2025-11-04 |
| Efficacy and Safety of Pemigatinib in Previously Treated Locally Advanced/Metastatic or Surgically Unresectable Solid Tumor Malignancies Harboring Activating FGFR Mutations or Translocations (FIGHT-207) Pemigatinib - Solid Tumor Malignancy | Phase 2 | Terminated | Incyte Corporation | 111 | 2019-10-17 | 2025-11-04 |
| Rogaratinib in Patients With Advanced Pretreated Squamous-cell Non-small Cell Lung Cancer (SQCLC) Rogaratinib - Squamous-cell Non-small Cell Lung Cancer | Phase 2 | Terminated | Swiss Cancer Institute | 15 | 2019-07-25 | 2022-11-09 |
| Irinotecan Plus Brivanib in Metastatic Colorectal Cancer (CRC) Enriched for Elevated Levels of Plasma FGF Brivanib, Irinotecan - Colorectal Cancer, Colorectal Adenocarcinoma | Phase 2 | Terminated | M.D. Anderson Cancer Center | 8 | 2011-08-01 | 2020-09-03 |
Acrocephalosyndactylia (5) · Carcinoma, Transitional Cell (1) · Colorectal Neoplasms (1) · Neoplasm Metastasis (1) · Stomach Neoplasms (1)
Bone Diseases (5) · Bone Diseases, Developmental (5) · Congenital Abnormalities (5) · Congenital, Hereditary, and Neonatal Diseases and Abnormalities (5) · Craniofacial Abnormalities (5) · Dysostoses (5) · Limb Deformities, Congenital (5) · Musculoskeletal Abnormalities (5) · Musculoskeletal Diseases (5) · Syndactyly (5) · Synostosis (5) · Neoplasms (3) · Digestive System Diseases (2) · Digestive System Neoplasms (2)
pemigatinib (2) · Carboplatin (1) · Gemcitabine (1) · Irinotecan (1) · Rogaratinib (1) · brivanib (1) · derazantinib (1) · pembrolizumab (1)
Incyte Corporation (2) · Basilea Pharmaceutica (1) · M.D. Anderson Cancer Center (1) · Swiss Cancer Institute (1)
United States (4) · France (3) · Germany (3) · Italy (3) · Spain (3) · United Kingdom (3) · Belgium (2) · Japan (2) · Poland (2) · South Korea (2) · Switzerland (2) · Argentina (1) · Australia (1) · Austria (1) · Brazil (1)
Alfredo Addeo, MD (1) · Luis Feliz Vinas, MD (1) · Michael Overman, MD (1) · Peter Langmuir, MD (1)
2018 (1), 2019 (1)